Clinical trial NCT04755023: Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
Official title: Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Oligodendroglioma; Oligoastrocytoma
Keywords: chemotherapy
BCNU-Temozolomide
radiotherapy
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2021-02-15
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with PCV, will be defined by the pending results of phase III of the EORTC.

If the phase II study proposed here achieves its objective, it may help define a new treatment regimen that will be compared to the standard arm from phase III of the EORTC.

In addition, this study, by prospectively testing the predictive value of 1p and 19q deletions and of REGF amplification, may allow characterization of patients using these markers. If validated, this characterization can constitute a key element in any therapeutic evaluation (patient stratification), and potentially a major tool for medical decision support in these tumors.


Eligibility criteria: Inclusion Criteria:

* Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma
* Tumor with measurable contrast enhancement (at least 15 mm in diameter)
* Surgical procedure limited to a biopsy or partial excision
* In the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by MRI, if not by CT, is required.
* Time between surgery and inclusion less than or equal to one and a half months (45 days)
* Age\> 18 years old; \<70
* Karnofsky index\> 60
* Stable or reduced dose of corticosteroids in the 15 days prior to inclusion
* Polynuclear neutrophils\> 1500; platelets\> 100,000
* Bilirubin \<1.25 x UNL; SGOT, SGPT, PAL \<2.5 x UNL
* Absence of serious uncontrolled pathology
* Patient having received and understood the information and having signed the consent

Exclusion Criteria:

* Presence of GBM foci within the tumor
* Absence of evaluable residue after surgery
* Previous chemotherapy or radiotherapy
* Unsatisfactory expected monitoring conditions
* Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age
* History of malignant disease (with the exception of CIS of the cervix and basal cell cancer)
* Contraindications related to the examination of the I.R.M.

Primary outcomes:
measure: Objective response rate of the BCNU-TMZ combination administered before radiotherapy
timeFrame: At the end of Cycle 2 (each cycle is 28 days)
measure: Objective response rate of the BCNU-TMZ combination administered before radiotherapy
timeFrame: At the end of Cycle 4 (each cycle is 28 days)
measure: Objective response rate of the BCNU-TMZ combination administered before radiotherapy
timeFrame: At the end of Cycle 6 (each cycle is 28 days)
measure: Objective response rate of the BCNU-TMZ combination administered before radiotherapy
timeFrame: 1 month after radiotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique - Hôpitaux de Marseille
Study officials:
References: